We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).
- Authors
Lim, Soo; Han, Kyung Ah; Yu, JaeMyung; Chamnan, Parinya; Kim, Eun Sook; Yoon, Kun-Ho; Kwon, Sam; Moon, Min Kyong; Lee, Kwan Woo; Kim, Dong-Jun; Kim, Mikyung; Wongtanate, Manaj; Kim, Eun Young; Kim, Sung-Ho; Lee, Moon-Kyu; INICOM Study Group
- Abstract
Gemigliptin is a new dipeptidyl peptidase-IV inhibitor. We investigated the efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes (T2D).
- Publication
Diabetes, obesity & metabolism, 2017, Vol 19, Issue 1, p87
- ISSN
1463-1326
- Publication type
Journal Article
- DOI
10.1111/dom.12787